A prospective, randomized, double-blind, placebo-controlled, pivotal trial of SQ 109 for multi-drug resistant tuberculosis in Russia.

Trial Profile

A prospective, randomized, double-blind, placebo-controlled, pivotal trial of SQ 109 for multi-drug resistant tuberculosis in Russia.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs SQ 109 (Primary) ; Antituberculars
  • Indications Pulmonary tuberculosis; Tuberculosis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 27 Mar 2017 Results published in an Infectex media release.
    • 24 Mar 2017 Status changed from recruiting to completed, as reported in an Infectex media release.
    • 24 Mar 2017 According to an Infectex media relesae, Prof. Sergey Borisov is principal investigator of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top